AMNOG
Early benefit assessment: Reviews and negotiations – Problems and conflicts
(© vfa / Golden Section Graphics - Dirk Aschoff)
When the legislature created the Act on the Restructuring of the Pharmaceutical Market (AMNOG), it has established a process that is as complex as it is complicated, and in some places it is questionable from a methodological standpoint. To facilitate an easier categorization of individual aspects of the procedure, we have developed an interactive information graphic in cooperation with ÄrzteZeitung that illustrates the process of the early benefit assessment, including the parties involved and the resulting problems and conflicts.
read on
read on
Country Report Germany – February 2012
General political situation
In contrast to most other European countries, Germany’s economy performed very well in 2011. As a result, the social security funds – especially the health fund – are well funded and show surpluses. Due to the uncertainties induced by the European...
read on
read on
In the Spotlight: Pharmaceutical expenditures
(© vfa)
Ways to achieve health care savings are currently being discussed. Governmental policy and the health insurancers plan to create these savings primarily by way of prescription drugs. Legislative decisions should be based on facts. Here are some facts regarding prices and spending on medicines in Germany.
read on
read on
Vaccine research and production: Europe is in the lead
(© GlaxoSmithKline)
Europe is in the lead when it comes to vaccines: This area covers two-thirds of industrial research and development activities, 60 percent of the employees and even 90 percent of worldwide production. A total of 84 percent of the European production is exported, half of it for humanitarian projects in developing countries.
read on
read on
Research & Development
More than 100 diseases to be better treatable by 2011
Drug sample for a clinical trial (© Amgen)
By the end of 2011, research-based pharmaceutical companies can obtain marketing authorization for 358 new pharmaceuticals or applications for existing drugs. Patients suffering from more than 100 different diseases, especially cancer patients for whom more than 25% of the new pharmaceuticals are developed, will be able to benefit from this development. These are results of a survey commissioned by the VFA.
read on
Innovative pharmaceuticals are kept from millions of patients
The Institute of Empirical Health Economics was commissioned by the German Association of Research-based Pharmaceutical Companies (VFA) to develop an expert report on the pharmaceutical care situation in Germany. The results have shown alarming health care gaps:
read on
read on
Strict rules for publication of post-marketing surveillance studies
In the future, the pharmaceutical companies organized in the German Association of Research-based Pharmaceutical Companies (VFA) will conduct and publish post-marketing surveillance studies according to stricter standards. As the VFA announced today,...
read on
read on
IW survey on "Germany's future industries"
The three industries of "Corporate Services," "Pharmaceuticals" and "Medical, Measuring and Control Technology" have the best future prospects out of 34 analyzed German industries. They benefit most strongly from expected technological and societal changes...
read on
read on
Drug Safety
Lessons from the Thalidomide Disaster
The greatest pharmaceuticals tragedy ever to take place occurred fifty years ago this year, when the sleeping pill and tranquillizer Thalidomide came onto the market. In the years that followed it caused serious deformities in children whose mothers had taken the drug during pregnancy.
read on
read on
G8 Development Summit
R&D Pharmaceutical Industry committed to improving health in Africa
The research-based pharmaceutical companies have long played a key role in international aid partnerships to improve health in Africa. Not only do they supply the latest medicines for diseases like HIV/ AIDS at cost and help African companies to manufacture...
read on
read on
Health care reform 2007
On April 1, 2007, the "Act for the Enhancement of Competition in Statutory Health Insurance" (SHI Competition Enhancement Act) will become effective in Germany. This reform will result in several structural changes for the financing of the German health care system:
read on
read on
Suggest page
Print page